A randomized, controlled, multicentre clinical study of Shengu Capsule in the treatment of postmenopausal osteoporosis (deficiency syndrome of liver and kidney)
- Conditions
- Postmenopausal Osteoporosis
- Registration Number
- ITMCTR2100004996
- Lead Sponsor
- Fujian Academy of Chinese Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- Not specified
1.Meet the diagnostic criteria for postmenopausal osteoporosis;
2.Meet the TCM syndrome differentiation standard of liver and kidney deficiency;
3.Voluntarily signed informed consent;
4.Age between 45 and 70 years old;
5.Female have been naturally menopausal for more than 1 yearr.
1.Those with secondary osteoporosis such as hyperparathyroidism, rheumatoid arthritis, multiple myeloma, type I diabetes, etc;
2.People with mental illness or Alzheimer's;
3.People with allergies or those who are known to be allergic to the ingredients in this medicine;
4.Those who are in a critical condition and are difficult to make an accurate assessment of the effectiveness and safety of the drug;
5.Patients with hypercalcemia and hypercalciuria.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Individual symptom score;VAS;TCM syndrome integral;25(OH)D;ALP;
- Secondary Outcome Measures
Name Time Method